The U.S. Food and Drug Administration (FDA) will convene an outside panel of experts to evaluate whether compounding pharmacies should be permitted to manufacture specific peptides for potential Alzheimer’s treatments, according to sources familiar with the matter. The move comes as demand for alternative therapies grows amid ongoing debates about the efficacy and accessibility of existing drugs.
Compounding pharmacies, which custom-mix medications, have increasingly sought to produce peptides that are not commercially available. The FDA’s interest follows a surge in off-label use of these compounds, despite limited clinical evidence supporting their effectiveness for neurodegenerative diseases. Analysts suggest the panel’s recommendations could set a precedent for how the agency regulates compounded biologics.
‘This is a critical juncture for patient access and safety,’ said one healthcare policy analyst, speaking on condition of anonymity. ‘The FDA must balance innovation with rigorous oversight.’
If approved, the move could expand treatment options for Alzheimer’s patients, but critics warn of potential risks from unproven therapies. The advisory committee’s findings are expected to influence broader FDA policy on compounded medications.